Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT7104 in advanced malignant tumors
NCT05767060Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAT7104 in cancer (7 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events. Started Jan 2022; status: completed.
02
Drugs
BAT7104
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05767060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05767060.